A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral F-02-2-Na Tablets in Adult Subjects

NCT07324434 · clinicaltrials.gov ↗

PHASE1

Phase

ENROLLING_BY_INVITATION

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperuricemia With or Without Gout

Interventions

DRUG: F-02-2-Na Tablet (0.5 mg)
DRUG: F-02-2-Na Matching Placebo (0.5mg)
DRUG: F-02-2-Na Tablet (5mg)
DRUG: F-02-2-Na Matching Placebo (5mg)
DRUG: F-02-2-Na Tablet (25mg)
DRUG: F-02-2-Na Matching Placebo (25mg)
DRUG: F-02-2-Na Tablet (75mg)
DRUG: F-02-2-Na Matching Placebo (75mg)
DRUG: F-02-2-Na Tablet (150 mg)
DRUG: F-02-2-Na Matching Placebo (150 mg)
DRUG: F-02-2-Na Tablet (200 mg)
DRUG: F-02-2-Na Matching Placebo (200 mg)
DRUG: F-02-2-Na Tablet (25mg)-Multiple dose
DRUG: F-02-2-Na Matching Placebo (25mg) -Multiple dose
DRUG: F-02-2-Na Tablet (50mg)-Multiple dose
DRUG: F-02-2-Na Matching Placebo (50mg) -Multiple dose
DRUG: F-02-2-Na Tablet (100mg)-Multiple dose
DRUG: F-02-2-Na Matching Placebo (100mg) -Multiple dose

Sponsor

Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd.

Collaborators

[object Object]
[object Object]